TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited

Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Central District of California on behalf of a class (the “Class”) consisting of persons and entities that purchased or otherwise acquired Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE: TEVA) securities between February 10, 2014 and November 3, 2016, inclusive (the “Class Period”).

If you are a member of the Class described above, you may move the Court no later than January 5, 2017, to serve as lead plaintiff. Please contact Lesley Portnoy at 888-773-9224 or 310-201-9150, or at [email protected] to discuss this matter.

On November 3, 2016, Bloomberg published the article “U.S. Charges in Generic-Drug Probe to Be Filed by Year End” which discussed the Department of Justice’s two year investigation of suspected price collusion by several pharmaceutical companies, including Teva, which will likely result in prosecutors filing criminal charges by the end of the year.

The complaint filed in this lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva and several of its pharmaceutical industry peers colluded to fix generic drug prices; (2) the foregoing conduct constituted a violation of federal antitrust laws; (3) consequently, Teva’s revenues during the Class Period were in part the result of illegal conduct; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.

If you purchased shares of Teva during the Class Period you may move the Court no later than January 5, 2017 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to [email protected], or visit our website at www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
27/12/2016

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Piv...

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stableS&P upgraded Teva to BB+ from BB, with a stable outlook TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term...

 PRESS RELEASE

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Bi...

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industri...

Teva Pharmaceutical Industries Ltd: 2 directors

Two Directors at Teva Pharmaceutical Industries Ltd sold 89,700 shares at between 30.204USD and 30.241USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...

 PRESS RELEASE

Teva Releases Q4 2025 Aide Memoire

Teva Releases Q4 2025 Aide Memoire TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website. Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva’s prior results, management’s previous co...

 PRESS RELEASE

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial ...

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance to obtain a local or toll-free phone number and your personal pin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch